EyePoint Pharmaceuticals, Inc. (EYPT) Stock Score, Valuation & Financial Research
EyePoint Pharmaceuticals, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 19/100.
Quick answer for EYPT
EyePoint Pharmaceuticals, Inc. currently has a Wall Street Score of 19/100. The stored market price is $3.66. Its financial score is 18/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What EyePoint Pharmaceuticals, Inc. does
EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the creation and marketing of ophthalmic solutions for various eye ailments. Its operations span the United States, China, and the United Kingdom. Among its commercialized product portfolio are ILUVIEN, an injectable, sustained-release micro-insert designed to treat diabetic macular edema, and YUTIQ, an intravitreal implant containing fluocinolone acetonide, which targets chronic non-infectious uveitis impacting the posterior segment of the eye. The company also offers DEXYCU, a dexamethasone intraocular suspension, utilized to manage post-operative ocular inflammation, such as that occurring after cataract surgery. Looking ahead, EyePoint is actively developing several pipeline therapies. This includes EYP-1901, a novel, bioerodible tyrosine kinase inhibitor currently formulated for twice-yearly administration, which i
EYPT financial snapshot
- Wall Street Score:
- 19/100
- Current price:
- $3.66
- Market capitalization:
- $306.9M
- Revenue:
- $2.8M
- Net income:
- $-306.6M
- Free cash flow:
- $-243.4M
- Cash:
- $110.5M
- Total debt:
- $22.4M
- EPS:
- -3.74
- Financial score:
- 18/100
- Valuation score:
- 0/100
- Revenue score:
- 0/100
What stands out
- Reported year-over-year revenue growth is -0.9%.
- Free cash flow is $-243.4M, showing cash burn in the current stored period.
- The balance sheet shows $110.5M of cash versus $22.4M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 18/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research EYPT
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.